Key result
ACE inhibition improved neovascularization in the diabetic ischemic leg but reduced vessel growth in the diabetic retina.
Why the study?
Does ACE inhibition or AT1 receptor blockade improve angiogenesis in ischemic limbs and reduce retinal neovascularization in type 1 diabetic mice?
Does ACE inhibition or AT1 receptor blockade improve angiogenesis in ischemic limbs and reduce retinal neovascularization in type 1 diabetic mice?
ACE inhibition exerts a dual effect in diabetic mice, improving ischemia-induced neovascularization in the leg via bradykinin signaling while reducing pathological vessel growth in the retina by inhibiting the Ang II pathway.
Answers are grounded in this paper and cite their sources.
ACE inhibition may exert tissue-specific angiogenic effects in diabetic models; leaves open translation to human limb or retinal disease.
OBJECTIVE: We analyzed the beneficial therapeutic effect of angiotensin converting enzyme inhibitor (ACEI) on both retinal and hind limb neovascularization in diabetic mice. METHODS AND RESULTS: Diabetic mice (streptozotocin, 40 mg/kg) were treated with or without ACEI (Perindopril, 3 mg/kg per day) or AT1 receptor blocker (Candesartan, 20 mg/kg) for 4 months. Hind limb ischemia was then induced by right femoral artery ligature for 1 additional month. In the ischemic leg, angiographic score, capillary density, and foot perfusion were increased by 2.7, 2.0-fold, and 1.6-fold, respectively, in ACEI-treated diabetic mice compared with untreated diabetic animals (P<0.01). ACEI also raised vascular endothelial growth factor (VEGF) protein level by 1.4-fold in ischemic diabetic leg. This ACEI pro-angiogenic effect was totally blunted in diabetic bradykinin B2 receptor-deficient animals, suggesting that it was mediated by the bradykinin pathway. In the diabetic retina, angiotensinogen and ACE mRNA levels were increased by 2.8-fold and 4.1-fold, respectively (P<0.01 versus nondiabetic mice), highlighting a local activation of renin-angiotensin system. Diabetes also raised VEGF protein level by 1.5-fold (P<0.05 versus nondiabetic mice). Treatments with ACEI and AT1 receptor blocker hampered diabetes-induced VEGF upregulation and retinal neovascularization. CONCLUSIONS: ACE inhibition improved neovascularization in the diabetic ischemic leg through activation of bradykinin signaling, whereas it reduced vessel growth in the diabetic retina through inhibition of overacting Ang II pathway.
No takes yet. Share an insight, caveat, or question.
Ebrahimian et al. (2004) studied Type 1 Diabetes with hind limb ischemia. ACEI (Perindopril) or AT1 receptor blocker (Candesartan) vs. Untreated diabetic animals was evaluated on Angiographic score, capillary density, and foot perfusion in ischemic leg (2.7-fold, 2.0-fold, and 1.6-fold increase, p=<0.01). ACE inhibition improved neovascularization in the diabetic ischemic leg but reduced vessel growth in the diabetic retina.
Synapse has enriched 10 related papers. Consider them for comparative context: